Truist Financial Lowers Astrana Health (NASDAQ:ASTH) Price Target to $50.00

Astrana Health (NASDAQ:ASTH) had its price objective lowered by Truist Financial from $59.00 to $50.00 in a research report report published on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research analysts also recently issued reports on the stock. BTIG Research upped their price target on shares of Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. TD Cowen initiated coverage on shares of Astrana Health in a research note on Monday, October 14th. They set a “buy” rating and a $66.00 target price on the stock. Robert W. Baird upped their price objective on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. KeyCorp assumed coverage on shares of Astrana Health in a report on Friday, October 11th. They set a “sector weight” rating on the stock. Finally, Macquarie upgraded Astrana Health to a “hold” rating in a research note on Monday, December 16th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Astrana Health currently has a consensus rating of “Moderate Buy” and an average target price of $63.67.

Astrana Health Stock Up 0.5 %

Astrana Health stock opened at $31.34 on Monday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The company’s 50-day moving average is $38.01 and its 200-day moving average is $46.80. The firm has a market capitalization of $1.76 billion, a PE ratio of 24.11, a P/E/G ratio of 1.80 and a beta of 1.20. Astrana Health has a fifty-two week low of $29.08 and a fifty-two week high of $63.20.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The firm had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. During the same period in the prior year, the firm posted $0.47 EPS. Sell-side analysts anticipate that Astrana Health will post 1.16 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Central Pacific Bank Trust Division bought a new position in shares of Astrana Health in the third quarter worth approximately $160,000. SG Americas Securities LLC bought a new stake in Astrana Health during the third quarter worth approximately $680,000. Granite Bay Wealth Management LLC bought a new position in Astrana Health during the third quarter valued at $290,000. Handelsbanken Fonder AB bought a new stake in Astrana Health in the third quarter worth about $492,000. Finally, GAMMA Investing LLC bought a new stake in shares of Astrana Health during the 3rd quarter worth approximately $34,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.